Novo Nordisk

News

Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.

News

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.

R&D

In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.

News

Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.

News

Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.

News

Novo Nordisk has said a real-world survey of Wegovy shows it can reduce 'food noise', persistent, intrusive, or repetitive thoughts about eating.